DAWN stock forecast
Our latest prediction for Day One Biopharmaceuticals Inc's stock price was made on the Nov. 25, 2022 when the stock price was at 21.41$.
In the short term (2weeks), DAWN's stock price should underperform the market by -4.25%. During that period the price should oscillate between -9.20% and +2.26%.
In the medium term (3months), DAWN's stock price should underperform the market by -3.93%. During that period the price should oscillate between -35.28% and +20.90%.Get email alerts
Create a solid portfolio with DAWN
About Day One Biopharmaceuticals Inc
Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers. Day One was founded to address a critical unmet need: children with cancer are being left behind in a cancer drug development revolution. Its name was inspired by the “The Day One Talk”1 that physicians have with patients and their families about an initial cancer diagnosis and treatment plan. The company aims to re-envision cancer drug development and redefine what’s possible for all people living with cancer—regardless of age—starting from Day One. Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important emerging cancer treatments. The Company’s lead product candidate, DAY101, is an oral, highly-selective type II pan-RAF kinase inhibitor, and is being evaluated in a pivotal Phase 2 clinical trial (FIREFLY-1) in pediatric, adolescent and young adult patients with recurrent or progressive low-grade glioma (pLGG). The Company’s pipeline also includes the investigational agent pimasertib, a clinical-stage, oral, small molecule found to selectively inhibit mitogen-activated protein kinase kinases 1 and 2 (MEK). Through Day One and its collaborators, cancer drug development comes of age. Day One is based in South San Francisco.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of None$ per share.
The book value per share is 4.80$
Three months stock forecastNov. 25, 2022
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|